Summit Therapeutics (SMMT) News Today $23.06 +1.46 (+6.76%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$23.11 +0.05 (+0.22%) As of 02/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period 3 Stocks That Could Trounce the Market in 2025February 17, 2025 | fool.comSummit Therapeutics (SMMT) Expected to Announce Quarterly Earnings on TuesdaySummit Therapeutics (NASDAQ:SMMT) will be releasing earnings before the market opens on Tuesday, February 18, Financial Modeling Prep reports.February 16, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.8% - What's Next?Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.8% - Should You Sell?February 14, 2025 | marketbeat.comSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 14, 2025 | businesswire.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.8% - Here's WhySummit Therapeutics (NASDAQ:SMMT) Shares Down 6.8% - Here's WhyFebruary 11, 2025 | marketbeat.comSovran Advisors LLC Purchases New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT)Sovran Advisors LLC acquired a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 117,174 shares of theFebruary 11, 2025 | marketbeat.comSummit Therapeutics (SMMT) Projected to Post Quarterly Earnings on TuesdaySummit Therapeutics (NASDAQ:SMMT) will be releasing earnings before the market opens on Tuesday, February 18, Financial Modeling Prep reports.February 11, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading Up 6% - Time to Buy?Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 6% - Still a Buy?February 10, 2025 | marketbeat.comIs Summit Therapeutics a Millionaire Maker?February 9, 2025 | fool.com2 Stocks That Could Soar Again in 2025February 8, 2025 | fool.comabrdn plc Boosts Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)abrdn plc lifted its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 13.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,290,425 shares of the company's stock after acquirFebruary 7, 2025 | marketbeat.comSG Americas Securities LLC Decreases Position in Summit Therapeutics Inc. (NASDAQ:SMMT)SG Americas Securities LLC decreased its position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 59.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,169 shares of the company's stock after selling 19,587 shares durFebruary 7, 2025 | marketbeat.comCalamos Advisors LLC Cuts Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)Calamos Advisors LLC decreased its position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 49.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,821 shares of the company's stock after selling 22,926 shares during thFebruary 6, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4% - Here's WhySummit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4% - Time to Sell?February 5, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading Down 5.4% - Here's What HappenedSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 5.4% - Should You Sell?February 3, 2025 | marketbeat.comAnalysts Set Summit Therapeutics Inc. (NASDAQ:SMMT) Price Target at $33.57Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating onFebruary 2, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Shares Purchased by China Universal Asset Management Co. Ltd.China Universal Asset Management Co. Ltd. increased its position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 12.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,366 shares of the company's stock after purchasFebruary 1, 2025 | marketbeat.comFive Pine Wealth Management Invests $531,000 in Summit Therapeutics Inc. (NASDAQ:SMMT)Five Pine Wealth Management acquired a new stake in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 29,746 shares of the company's stock, valued at approximately $531,February 1, 2025 | marketbeat.comUp More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock?January 30, 2025 | fool.comSummit Therapeutics Inc. (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by AnalystsSummit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recJanuary 30, 2025 | marketbeat.comIs Summit Therapeutics Inc. (SMMT) the Unstoppable Stock to Buy in 2025?January 30, 2025 | msn.comGriffin Asset Management Inc. Boosts Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)Griffin Asset Management Inc. increased its stake in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 63.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,660 shares of the companyJanuary 28, 2025 | marketbeat.comAssenagon Asset Management S.A. Buys New Stake in Summit Therapeutics Inc. (NASDAQ:SMMT)Assenagon Asset Management S.A. purchased a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,824 shares of theJanuary 26, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.7% - Time to Sell?Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.7% - Time to Sell?January 24, 2025 | marketbeat.com3 Unstoppable Stocks to Buy That Wall Street Thinks Will Soar More Than 35%January 23, 2025 | fool.comSummit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $44.00 price target on shares of Summit Therapeutics in a research note on Tuesday.January 22, 2025 | marketbeat.comWhy Summit Therapeutics Stock Is Jumping TodayJanuary 21, 2025 | fool.comSummit Therapeutics: A Promising Investment with Strategic Progress and Strong Financial FoundationJanuary 21, 2025 | markets.businessinsider.comSummit Therapeutics retains Buy stock rating on clinical trialJanuary 21, 2025 | msn.comHC Wainwright Reaffirms "Buy" Rating for Summit Therapeutics (NASDAQ:SMMT)HC Wainwright reaffirmed a "buy" rating and set a $44.00 target price on shares of Summit Therapeutics in a research report on Tuesday.January 21, 2025 | marketbeat.comIs Summit Therapeutics (SMMT) the Best Russell 2000 Stock to Invest in According to Analysts?January 18, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Trading 6.5% Higher - What's Next?Summit Therapeutics (NASDAQ:SMMT) Trading Up 6.5% - Time to Buy?January 17, 2025 | marketbeat.com24,879 Shares in Summit Therapeutics Inc. (NASDAQ:SMMT) Acquired by SeaCrest Wealth Management LLCSeaCrest Wealth Management LLC acquired a new position in shares of Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 24,879 shares of the company's stock, valued at approJanuary 17, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Trading Down 6.3% - Here's What HappenedSummit Therapeutics (NASDAQ:SMMT) Trading Down 6.3% - What's Next?January 16, 2025 | marketbeat.comWhy Summit Therapeutics Rocketed 584% in 2024January 15, 2025 | fool.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.3% - Time to Sell?Summit Therapeutics (NASDAQ:SMMT) Trading Down 6.3% - What's Next?January 14, 2025 | marketbeat.comTruist Securities Initiates Coverage of Summit Therapeutics (SMMT) with Buy RecommendationJanuary 9, 2025 | msn.comMerck rival Summit draws new buy from Truist on deal prospectsJanuary 8, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Up 3.3% - Time to Buy?Summit Therapeutics (NASDAQ:SMMT) Trading Up 3.3% - Time to Buy?January 8, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at Truist FinancialTruist Financial started coverage on Summit Therapeutics in a research note on Wednesday. They set a "buy" rating and a $35.00 price objective for the company.January 8, 2025 | marketbeat.comSummit Therapeutics Inc. (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSummit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy reJanuary 5, 2025 | marketbeat.comPrediction: These 3 Healthcare Stocks Will Soar in 2025January 4, 2025 | fool.comWhy Is Summit Therapeutics Inc. (SMMT) Among the Best Multibagger Stocks to Buy Right Now?January 1, 2025 | msn.com3 Stocks That Could Be Monster Winners in 2025December 29, 2024 | fool.comSummit Therapeutics (NASDAQ:SMMT) Trading Down 6.2% - Here's WhySummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2% - Should You Sell?December 27, 2024 | marketbeat.comFranklin Resources Inc. Takes Position in Summit Therapeutics Inc. (NASDAQ:SMMT)Franklin Resources Inc. acquired a new position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 103,276 shares of the company's stock, valued at approximately $December 27, 2024 | marketbeat.comIs Summit Therapeutics Inc. (SMMT) the Best Performing Biotech Stock in 2024?December 23, 2024 | insidermonkey.comGeode Capital Management LLC Has $67.90 Million Stock Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT)Geode Capital Management LLC increased its position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 4.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,099,808 shares of the company's stock after purchasing an additional 13December 22, 2024 | marketbeat.comBarclays PLC Lowers Stake in Summit Therapeutics Inc. (NASDAQ:SMMT)Barclays PLC lessened its position in Summit Therapeutics Inc. (NASDAQ:SMMT - Free Report) by 35.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 250,118 shares of the company's stock after sellingDecember 21, 2024 | marketbeat.comWhy These 10 Stocks Jumped YesterdayDecember 20, 2024 | insidermonkey.com Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address SMMT Media Mentions By Week SMMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼0.440.60▲Average Medical News Sentiment SMMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼45▲SMMT Articles Average Week Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today Genmab A/S News Today Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
